Generate:Biomedicines announced it is initiating two Phase 3 studies of its lead TSLP (thymic stromal lymphopoietin) antibody, marking a major clinical inflection for an AI‑driven biotech. The Somerville, MA company said the trials will evaluate efficacy and safety in large patient cohorts as it positions the asset for regulatory approval. Generate’s platform uses machine‑learning methods to design and optimize biologics; the move to Phase 3 validates its translational pipeline and will test whether computationally accelerated discovery can shorten timelines and de‑risk late‑stage programs. The trials will provide pivotal data on clinical benefit and inform commercial strategy.